# Program 12: Developmental Therapeutics

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2021 · $93,161

## Abstract

Developmental Therapeutics Program 
Project Summary / Abstract 
The Developmental Therapeutics Program comprises a highly collaborative effort in early phase drug 
development that serves as a magnet for bringing promising new anti-cancer drugs from the NCI, DF/HCC 
investigators and industry through the earliest phase of clinical evaluation. The Program is thus tightly 
integrated with Disease Programs and actively transitions drugs from early to later phase development. In 
addition, the Program is closely aligned with other Programs and Centers that focus on drug discovery and 
biomarker development, as well as aspects of cancer biology that include signal transduction, cell cycle 
regulation, DNA repair and immuno-oncology. Three Specific Aims are planned over the next 5 years: (1) To 
conduct Phase I and I-II clinical trials of new anti-cancer agents and combinations with safety, 
pharmacokinetic, pharmacodynamic and preliminary efficacy endpoints; (2) To validate biomarkers for drug 
response, resistance, and toxicity; and (3) To provide mentoring and career development support for fellows 
and junior faculty in early drug development. The program has 58 members, representing six DF/HCC 
institutions and 11 academic departments. In 2014 peer-reviewed grant funding attributed to the Program was 
$3.7 million in total costs from the NCI and $0.3 million from other sponsors. During the current funding period, 
Developmental Therapeutics Program members published 1,364 cancer-relevant papers. Of these 28% were 
inter-institutional, 13% were intra-programmatic, and 59% were inter-programmatic collaborations between two 
or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter- 
programmatic collaborations.

## Key facts

- **NIH application ID:** 10062933
- **Project number:** 5P30CA006516-56
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** Geoffrey I. Shapiro
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $93,161
- **Award type:** 5
- **Project period:** 1997-03-10 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10062933

## Citation

> US National Institutes of Health, RePORTER application 10062933, Program 12: Developmental Therapeutics (5P30CA006516-56). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10062933. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*